December 8, 2025BloodOpen Access

Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia

View Full Paper

Ask AI

Bookmark

Letermovir significantly reduced CMV infection rates in children receiving hematopoietic stem cell transplantation, showing the importance of prophylaxis.
In the study, the survival rate was achieved at 80%, slightly higher than the control group's 76.67%, indicating positive outcomes with letermovir use.
Hematopoietic stem cell transplantation was performed on 53 children with acute leukemia, comparing those receiving letermovir to those receiving standard care
This suggests that letermovir may improve outcomes in pediatric patients, minimizing the risk of infections and graft-versus-host disease.

Discussion

No takes yet. Share an insight, caveat, or question.

Analysis shows letermovir reduces CMV infections in children with leukemia post hematopoietic stem cell transplantation, improving survival rates.

Zhijie Wei (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis shows letermovir reduces CMV infections in children with leukemia post hematopoietic stem cell transplantation, improving survival rates.